AU2015227184B2 - Improved reprogramming methods and cell culture platforms - Google Patents

Improved reprogramming methods and cell culture platforms Download PDF

Info

Publication number
AU2015227184B2
AU2015227184B2 AU2015227184A AU2015227184A AU2015227184B2 AU 2015227184 B2 AU2015227184 B2 AU 2015227184B2 AU 2015227184 A AU2015227184 A AU 2015227184A AU 2015227184 A AU2015227184 A AU 2015227184A AU 2015227184 B2 AU2015227184 B2 AU 2015227184B2
Authority
AU
Australia
Prior art keywords
cells
cell
inhibitor
pluripotent
oct4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015227184A
Other languages
English (en)
Other versions
AU2015227184A1 (en
Inventor
Ramzey ABUJAROUR
Peter Flynn
Megan ROBINSON
Bahram Valamehr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of AU2015227184A1 publication Critical patent/AU2015227184A1/en
Application granted granted Critical
Publication of AU2015227184B2 publication Critical patent/AU2015227184B2/en
Priority to AU2021218109A priority Critical patent/AU2021218109B2/en
Priority to AU2024205273A priority patent/AU2024205273A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/724—Glycosyltransferases (EC 2.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2015227184A 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms Active AU2015227184B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021218109A AU2021218109B2 (en) 2014-03-04 2021-08-19 Improved reprogramming methods and cell culture platforms
AU2024205273A AU2024205273A1 (en) 2014-03-04 2024-07-31 Improved reprogramming methods and cell culture platforms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947979P 2014-03-04 2014-03-04
US61/947,979 2014-03-04
PCT/US2015/018801 WO2015134652A1 (en) 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021218109A Division AU2021218109B2 (en) 2014-03-04 2021-08-19 Improved reprogramming methods and cell culture platforms

Publications (2)

Publication Number Publication Date
AU2015227184A1 AU2015227184A1 (en) 2016-09-15
AU2015227184B2 true AU2015227184B2 (en) 2021-05-20

Family

ID=54055848

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015227184A Active AU2015227184B2 (en) 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms
AU2021218109A Active AU2021218109B2 (en) 2014-03-04 2021-08-19 Improved reprogramming methods and cell culture platforms
AU2024205273A Pending AU2024205273A1 (en) 2014-03-04 2024-07-31 Improved reprogramming methods and cell culture platforms

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021218109A Active AU2021218109B2 (en) 2014-03-04 2021-08-19 Improved reprogramming methods and cell culture platforms
AU2024205273A Pending AU2024205273A1 (en) 2014-03-04 2024-07-31 Improved reprogramming methods and cell culture platforms

Country Status (11)

Country Link
US (2) US11268069B2 (https=)
EP (4) EP3114214B1 (https=)
JP (7) JP6722108B2 (https=)
KR (4) KR20240091064A (https=)
CN (3) CN106414721A (https=)
AU (3) AU2015227184B2 (https=)
CA (1) CA2941004A1 (https=)
ES (2) ES2966757T3 (https=)
PT (1) PT3114214T (https=)
SG (2) SG11201606934SA (https=)
WO (1) WO2015134652A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087965A2 (en) 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
SG11201606934SA (en) * 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
US10023879B2 (en) * 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
RU2018106515A (ru) 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
SG10202111851YA (en) * 2015-10-16 2021-12-30 Fate Therapeutics Inc Platform for the Induction & Maintenance of Ground State Pluripotency
US20190093072A1 (en) 2015-10-21 2019-03-28 Indiana University Research And Technology Corporation Methods of generating human inner ear sensory epithelia and sensory neurons
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
EP3402496A4 (en) * 2016-01-12 2019-06-19 Lonza Walkersville, Inc. METHOD AND VECTORS FOR PRODUCING VECTOR-FREE INDUCED PLURIPOTENTER STEM CELLS
WO2018124118A1 (ja) * 2016-12-27 2018-07-05 住友化学株式会社 人工多能性幹細胞の評価方法及び選抜方法、並びに人工多能性幹細胞の製造方法
CN106754729B (zh) * 2016-12-31 2020-03-17 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
JP7554670B2 (ja) 2017-10-11 2024-09-20 フェイト セラピューティクス，インコーポレイテッド 一時的かつ一過性プラスミドベクター発現システムを用いる細胞のリプログラミング
CA3083779A1 (en) 2017-12-22 2019-06-27 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
KR20250051148A (ko) * 2017-12-28 2025-04-16 더 제이. 데이비드 글래드스톤 인스티튜트, 어 테스터멘터리 트러스트 이스타빌리쉬드 언더 더 윌 오브 제이. 데이비드 글래드스톤 Crispr 활성화에 의한 유도 만능 세포의 생성
EP3768827A1 (en) * 2018-03-22 2021-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for reprogramming somatic cells
MX2021003663A (es) 2018-09-28 2021-05-28 Harvard College Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos.
KR102943217B1 (ko) 2018-12-02 2026-03-25 페이트 세러퓨틱스, 인코포레이티드 향상된 iPSC 유래 효과기 세포를 사용한 면역요법
CN109679918A (zh) * 2018-12-25 2019-04-26 合肥中科干细胞再生医学有限公司 一种便捷的人诱导性多能干细胞的制备方法
WO2020203712A1 (ja) * 2019-03-29 2020-10-08 富士フイルム株式会社 特定細胞に分化する能力を有する多能性幹細胞の製造方法およびその応用
CN110564673A (zh) * 2019-09-26 2019-12-13 广东工业大学 一种干细胞培养液及其应用
KR20220113349A (ko) * 2019-12-11 2022-08-12 리페아론 게엠베하 생물반응기의 현탁액에서 줄기세포의 확장
AU2021292695A1 (en) 2020-06-19 2023-02-02 Fate Therapeutics, Inc. Combining iPSC-derived effector cell types for immunotherapy use
US20210395698A1 (en) * 2020-06-22 2021-12-23 Life Technologies Corporation Methods and compositions for cultivating pluripotent cell suspensions
AU2021353586A1 (en) * 2020-10-02 2023-05-11 Fate Therapeutics, Inc. Improved reprogramming, maintenance and preservation for induced pluripotent stem cells
US20230302044A1 (en) * 2022-03-28 2023-09-28 Steve Reilly Composition to increase cellularlongevity
EP4504914A4 (en) 2022-04-08 2026-04-29 Fate Therapeutics Inc Cells having solid tumor targeting backbone and use thereof
CA3247010A1 (en) 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
JP2025534025A (ja) * 2022-10-12 2025-10-09 北京大学 化学的リプログラミング方法及び多能性幹細胞
WO2025152036A1 (en) * 2024-01-16 2025-07-24 Chiou Guang Yuh System and method for increasing the transduction capability and reprogramming efficiency in targeting cells and tissues
WO2025208002A1 (en) * 2024-03-28 2025-10-02 Altos Labs, Inc. Targeted expression of regeneration factors in aged/senescent cells
CN118979011A (zh) * 2024-10-22 2024-11-19 杭州瑞普晨创科技有限公司 人多能干细胞单细胞的建系方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087965A2 (en) * 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DK0641781T3 (da) 1991-09-06 2000-09-18 Yoshitomi Pharmaceutical 4-Amino(alkyl)cyclohexan-1-carboxamidforbindelser og anvendelse af disse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0710283A4 (en) 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
EP0981352B8 (en) 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
JP3626206B2 (ja) 1997-06-13 2005-03-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ６及びその使用
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
US6800790B2 (en) 1998-07-24 2004-10-05 Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the TFG-β family of growth factors
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
AU5250400A (en) 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
WO2001017562A1 (fr) 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
MXPA03008659A (es) 2001-03-23 2005-04-08 Bayer Ag Inhibidores de rho-cinasa.
ATE452972T1 (de) 2001-05-01 2010-01-15 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
CA2461185A1 (en) 2001-09-21 2003-04-03 Japan Science And Technology Corporation Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
PT1456380E (pt) 2001-11-02 2012-07-23 Giuliani Int Ltd Inibidores smad7 para o tratamento de doenças do snc
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1500643A4 (en) 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co benzamidine
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
JP2006508974A (ja) 2002-11-15 2006-03-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 癌を治療するためのｍｅｋ阻害剤およびカペシタビン（ｃａｐｅｃｉｔａｂｉｎｅ）を含む併用化学療法
US7265138B2 (en) 2003-02-10 2007-09-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
CA2529752A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
AU2004278634B2 (en) 2003-10-03 2009-10-01 Keiichi Fukuda Method of inducing the differentiation of stem cells into cardiomyocytes
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
AU2004281309A1 (en) 2003-10-16 2005-04-28 The University Court Of The University Of Edinburgh Control of ES cell self-renewal and lineage specification, and medium therefor
WO2005049812A1 (en) 2003-11-19 2005-06-02 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
WO2005074643A2 (en) 2004-01-30 2005-08-18 Smithkline Beecham Corporation Benzamide compounds useful as rock inhibitors
ES2400567T3 (es) 2004-04-21 2013-04-10 The University Of Chicago Inhibidores de cinasa de la cadena ligera de miosina y su uso
EP1791952A4 (en) 2004-08-13 2008-06-11 Univ Georgia Res Found COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS
US20080268533A1 (en) 2004-08-25 2008-10-30 University Of Georgia Research Foundation, Inc. Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells
WO2006088867A2 (en) 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
SG177981A1 (en) 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
US7601699B2 (en) 2005-08-01 2009-10-13 Nupotential, Inc. Production of reprogrammed cells with restored potential
WO2007030693A2 (en) 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
BRPI0619794B8 (pt) 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP2457995A1 (en) 2006-03-30 2012-05-30 The University Court of The University of Edinburgh Culture medium containing kinase inhibitors, and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
GB2452186B (en) 2006-05-02 2011-01-26 Wisconsin Alumni Res Found Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
CN101595107A (zh) 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
BRPI0714409A2 (pt) 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
ZA200901914B (en) 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
WO2008089351A1 (en) 2007-01-17 2008-07-24 Wisconsin Alumni Research Foundation Improved culture of stem cells
WO2008088882A2 (en) 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
CN103627671A (zh) 2007-01-30 2014-03-12 佐治亚大学研究基金会 产生中内胚层细胞及多能游走细胞的方法与细胞群及用途
WO2008105630A1 (en) 2007-02-27 2008-09-04 Procell Therapeutics Inc. Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells
ES2703592T3 (es) 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
ES2527444T5 (es) 2007-04-18 2018-05-17 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
US7878210B2 (en) 2007-06-04 2011-02-01 Philip Morris Usa Inc. Cellulose acetate fiber modification
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US8815585B2 (en) 2007-06-29 2014-08-26 Cellular Dynamics International, Inc. Automated method and apparatus for embryonic stem cell culture
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
AU2008297011B2 (en) 2007-08-31 2014-06-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
US20110151447A1 (en) 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
WO2009073523A2 (en) 2007-11-29 2009-06-11 Children's Hospital Of Orange County De-differentiation of human cells
WO2009067757A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving oct4 protein
AU2008329562A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Sox2 protein
SG188904A1 (en) 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US20110061118A1 (en) 2008-03-17 2011-03-10 Helmholtz Zentrum Munchen Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
WO2010013845A1 (en) * 2008-07-30 2010-02-04 Kyoto University Method of efficiently establishing induced pluripotent stem cells
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
EP2356213B1 (en) 2008-11-04 2019-05-29 Viacyte, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
EP4585589A3 (en) 2008-12-03 2025-11-19 The Scripps Research Institute Stem cell cultures
BRPI0922572A2 (pt) 2008-12-17 2019-09-24 Scripps Research Inst método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
CA2688804A1 (en) * 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic vector for human induced pluripotent stem cell production
CN101792776B (zh) * 2009-02-01 2013-12-11 中国人民解放军第二军医大学东方肝胆外科医院 一种高效诱导多能性干细胞的重组腺病毒载体、使用该载体的诱导方法及其用途
WO2010102267A2 (en) 2009-03-06 2010-09-10 Ipierian, Inc. Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
KR20110134939A (ko) * 2009-04-03 2011-12-15 더 맥클린 하스피털 코퍼레이션 유도된 다능성 줄기 세포
CN102395672A (zh) 2009-04-13 2012-03-28 加利福尼亚大学董事会 用于干细胞培养的方法和组合物
CA2763482A1 (en) 2009-05-27 2010-12-02 The Salk Institute For Biological Studies Generation of genetically corrected disease-free induced pluripotent stem cells
US8524498B2 (en) 2009-05-29 2013-09-03 The General Hospital Corporation Methods and compositions for homologous recombination in human cells
US9005975B2 (en) 2009-05-29 2015-04-14 Kyoto University Method for selecting clone of induced pluripotent stem cells
DK2438160T3 (en) 2009-06-05 2016-01-11 Cellular Dynamics Int Inc Reprogramming of T cells and hematopoietic cells
KR101774206B1 (ko) 2009-08-07 2017-09-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도된 다능성 줄기 세포의 효율적인 확립 방법
AU2010306627B2 (en) 2009-10-16 2014-07-17 The Scripps Research Institute Induction of pluripotent cells
CA2779310C (en) 2009-10-31 2021-11-30 New World Laboratories Inc. Methods for reprogramming cells and uses thereof
ES2539487T3 (es) 2009-11-04 2015-07-01 Cellular Dynamics International, Inc. Reprogramación episómica con compuestos químicos
EP3633025B1 (en) * 2009-11-12 2022-09-14 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
US20130011918A1 (en) 2010-02-17 2013-01-10 Biotime Inc. Methods for telomere length and genomic dna quality control and analysis in pluripotent stem cells
WO2011109695A1 (en) 2010-03-05 2011-09-09 Texas Heart Institute Ets2 and mesp1 generate cardiac progenitors from fibroblasts
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
JPWO2011158852A1 (ja) 2010-06-15 2013-08-19 国立大学法人 東京大学 誘導型多能性幹細胞の製造方法
JP5984217B2 (ja) 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
WO2012018933A2 (en) 2010-08-04 2012-02-09 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
DK3257943T3 (da) * 2010-11-02 2019-10-21 Helmholtz Zentrum Infektionsforschung Gmbh Fremgangsmåder og vektorer til celleimmortalisering
US9458131B2 (en) * 2011-11-08 2016-10-04 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
CA2858069C (en) 2011-12-08 2020-02-11 Novartis Ag Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
EP2853590B1 (en) 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
SG10202111851YA (en) 2015-10-16 2021-12-30 Fate Therapeutics Inc Platform for the Induction & Maintenance of Ground State Pluripotency
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087965A2 (en) * 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs

Also Published As

Publication number Publication date
JP6722108B2 (ja) 2020-07-15
JP2019187454A (ja) 2019-10-31
SG10201807292YA (en) 2018-09-27
KR20210111884A (ko) 2021-09-13
ES3050608T3 (en) 2025-12-22
KR102670874B1 (ko) 2024-05-31
JP7516452B2 (ja) 2024-07-16
EP4647498A2 (en) 2025-11-12
JP2018086018A (ja) 2018-06-07
AU2015227184A1 (en) 2016-09-15
WO2015134652A1 (en) 2015-09-11
JP2023126627A (ja) 2023-09-07
JP7738035B2 (ja) 2025-09-11
US11268069B2 (en) 2022-03-08
US20170073643A1 (en) 2017-03-16
EP3114214A1 (en) 2017-01-11
AU2021218109A1 (en) 2021-09-09
EP3805369B1 (en) 2025-09-03
SG11201606934SA (en) 2016-09-29
AU2021218109B2 (en) 2024-05-02
KR102340553B1 (ko) 2021-12-21
KR20240091064A (ko) 2024-06-21
CN120536341A (zh) 2025-08-26
EP3805369C0 (en) 2025-09-03
KR20160130260A (ko) 2016-11-10
ES2966757T3 (es) 2024-04-24
PT3114214T (pt) 2024-01-03
CN120536340A (zh) 2025-08-26
JP2025114793A (ja) 2025-08-05
EP3114214A4 (en) 2017-08-09
KR102460549B1 (ko) 2022-10-28
US20220228125A1 (en) 2022-07-21
JP2022082668A (ja) 2022-06-02
JP7170600B2 (ja) 2022-11-14
EP3114214B1 (en) 2023-11-01
EP3805369A1 (en) 2021-04-14
AU2024205273A1 (en) 2024-08-22
KR20220147728A (ko) 2022-11-03
CA2941004A1 (en) 2015-09-11
EP4647498A3 (en) 2026-01-28
JP2021000107A (ja) 2021-01-07
JP2017506904A (ja) 2017-03-16
EP3604499A1 (en) 2020-02-05
CN106414721A (zh) 2017-02-15

Similar Documents

Publication Publication Date Title
AU2021218109B2 (en) Improved reprogramming methods and cell culture platforms
US12351831B2 (en) Platform for the induction and maintenance of ground state pluripotency
HK40051615B (en) Improved reprogramming methods and cell culture platforms
HK40051615A (en) Improved reprogramming methods and cell culture platforms
HK40012687A (en) Improved reprogramming methods and cell culture platforms
HK1229376A1 (en) Improved reprogramming methods and cell culture platforms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)